🚀 VC round data is live in beta, check it out!
Genovis Valuation Multiples
Discover revenue and EBITDA valuation multiples for Genovis and similar public comparables like Euroapi, Prestige Biologics, Selvita, Savior Lifetec and more.
Genovis Overview
About Genovis
Genovis AB offers customers in the biopharmaceutical and research industries tools that facilitate and save time in the development of new treatment methods and diagnostics. Its enzyme products, known as SmartEnzymes, are used by scientists all over the world, and the product formats facilitate the development and quality control of biological drugs. Its products include Enzyme and Antibodies. Geographically, it operates in Sweden and Rest of the world.
Founded
1999
HQ
Employees
38
Website
Financials (LTM)
EV
$135M
Genovis Financials
Genovis reported last 12-month revenue of $15M and EBITDA of $4M.
In the same LTM period, Genovis generated $13M in gross profit, $4M in EBITDA, and $2M in net income.
Revenue (LTM)
Genovis P&L
In the most recent fiscal year, Genovis reported revenue of $14M and EBITDA of $4M.
Genovis expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $15M | XXX | $14M | XXX | XXX | XXX |
| Gross Profit | $13M | XXX | $13M | XXX | XXX | XXX |
| Gross Margin | 90% | XXX | 87% | XXX | XXX | XXX |
| EBITDA | $4M | XXX | $4M | XXX | XXX | XXX |
| EBITDA Margin | 28% | XXX | 26% | XXX | XXX | XXX |
| EBIT Margin | 18% | XXX | 16% | XXX | XXX | XXX |
| Net Profit | $2M | XXX | $3M | XXX | XXX | XXX |
| Net Margin | 17% | XXX | 18% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Genovis Stock Performance
Genovis has current market cap of $145M, and enterprise value of $135M.
Market Cap Evolution
Genovis' stock price is $2.19.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $135M | $145M | 0.3% | XXX | XXX | XXX | $0.04 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialGenovis Valuation Multiples
Genovis trades at 9.0x EV/Revenue multiple, and 32.3x EV/EBITDA.
EV / Revenue (LTM)
Genovis Financial Valuation Multiples
As of April 19, 2026, Genovis has market cap of $145M and EV of $135M.
Equity research analysts estimate Genovis' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Genovis has a P/E ratio of 58.0x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $145M | XXX | $145M | XXX | XXX | XXX |
| EV (current) | $135M | XXX | $135M | XXX | XXX | XXX |
| EV/Revenue | 9.0x | XXX | 9.3x | XXX | XXX | XXX |
| EV/EBITDA | 32.3x | XXX | 35.8x | XXX | XXX | XXX |
| EV/EBIT | 49.2x | XXX | 56.5x | XXX | XXX | XXX |
| EV/Gross Profit | 10.1x | XXX | 10.7x | XXX | XXX | XXX |
| P/E | 58.0x | XXX | 56.5x | XXX | XXX | XXX |
| EV/FCF | (124.9x) | XXX | 38.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Genovis Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Genovis Margins & Growth Rates
Genovis' revenue in the last 12 month grew by 16%.
Genovis' revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.3M for the same period.
Genovis' rule of 40 is 46% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Genovis' rule of X is 67% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Genovis Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 16% | XXX | 11% | XXX | XXX | XXX |
| EBITDA Margin | 28% | XXX | 26% | XXX | XXX | XXX |
| EBITDA Growth | 40% | XXX | 37% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 46% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 67% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.4M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.3M | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 71% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Genovis Public Comps
See public comps and valuation multiples for other Contract Research & Manufacturing comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Genovis | XXX | XXX | XXX | XXX | XXX | XXX |
| Euroapi | XXX | XXX | XXX | XXX | XXX | XXX |
| Prestige Biologics | XXX | XXX | XXX | XXX | XXX | XXX |
| Selvita | XXX | XXX | XXX | XXX | XXX | XXX |
| Savior Lifetec | XXX | XXX | XXX | XXX | XXX | XXX |
| Mycenax Biotech | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Genovis M&A Activity
Genovis acquired XXX companies to date.
Last acquisition by Genovis was on XXXXXXXX, XXXXX. Genovis acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Genovis
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialGenovis Investment Activity
Genovis invested in XXX companies to date.
Genovis made its latest investment on XXXXXXXX, XXXXX. Genovis invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Genovis
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Genovis
| When was Genovis founded? | Genovis was founded in 1999. |
| Where is Genovis headquartered? | Genovis is headquartered in Sweden. |
| How many employees does Genovis have? | As of today, Genovis has over 38 employees. |
| Is Genovis publicly listed? | Yes, Genovis is a public company listed on Nasdaq Stockholm. |
| What is the stock symbol of Genovis? | Genovis trades under GENO ticker. |
| When did Genovis go public? | Genovis went public in 2005. |
| Who are competitors of Genovis? | Genovis main competitors are Euroapi, Prestige Biologics, Selvita, Savior Lifetec. |
| What is the current market cap of Genovis? | Genovis' current market cap is $145M. |
| What is the current revenue of Genovis? | Genovis' last 12 months revenue is $15M. |
| What is the current revenue growth of Genovis? | Genovis revenue growth (NTM/LTM) is 16%. |
| What is the current EV/Revenue multiple of Genovis? | Current revenue multiple of Genovis is 9.0x. |
| Is Genovis profitable? | Yes, Genovis is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Genovis? | Genovis' last 12 months EBITDA is $4M. |
| What is Genovis' EBITDA margin? | Genovis' last 12 months EBITDA margin is 28%. |
| What is the current EV/EBITDA multiple of Genovis? | Current EBITDA multiple of Genovis is 32.3x. |
| What is the current FCF of Genovis? | Genovis' last 12 months FCF is ($1M). |
| What is Genovis' FCF margin? | Genovis' last 12 months FCF margin is (7%). |
| What is the current EV/FCF multiple of Genovis? | Current FCF multiple of Genovis is (124.9x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.